Abstract
We present the case of a 77-year-old female with seven non-locally advanced basal cell carcinomas (BCCs) of the face who achieved a clinical complete response (CR) in six lesions after completing twelve months of Vismodegib monotherapy with tolerable side effects. This case investigates the off-label practical use of Vismodegib monotherapy to treat multiple non-locally advanced BCCs and reduce the surgical burden of disease in select patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
